Back to Search
Start Over
The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential
- Source :
- Cancer Communications, Cancer Communications, Vol 41, Iss 10, Pp 981-1006 (2021)
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Oral squamous cell carcinoma (OSCC), the eighth most prevalent cancer in the world, arises from the interaction of multiple factors including tobacco, alcohol consumption, and betel quid. Chemotherapeutic agents such as cisplatin, 5‐fluorouracil, and paclitaxel have now become the first‐line options for OSCC patients. Nevertheless, most OSCC patients eventually acquire drug resistance, leading to poor prognosis. With the discovery and identification of non‐coding RNAs (ncRNAs), the functions of dysregulated ncRNAs in OSCC development and drug resistance are gradually being widely recognized. The mechanisms of drug resistance of OSCC are intricate and involve drug efflux, epithelial‐mesenchymal transition, DNA damage repair, and autophagy. At present, strategies to explore the reversal of drug resistance of OSCC need to be urgently developed. Nano‐delivery and self‐cellular drug delivery platforms are considered as effective strategies to overcome drug resistance due to their tumor targeting, controlled release, and consistent pharmacokinetic profiles. In particular, the combined application of new technologies (including CRISPR systems) opened up new horizons for the treatment of drug resistance of OSCC. Hence, this review explored emerging regulatory functions of ncRNAs in drug resistance of OSCC, elucidated multiple ncRNA‐meditated mechanisms of drug resistance of OSCC, and discussed the potential value of drug delivery platforms using nanoparticles and self‐cells as carriers in drug resistance of OSCC.<br />The mechanisms of drug resistance are intricate and involve drug efflux, epithelial mesenchymal transition, DNA damage repair, and autophagy. Nano‐delivery and self‐cellular drug delivery platforms have a broad prospective for alleviating OSCC drug resistance. In particular, the combined application of new technologies (including CRISPR systems) opens up new horizons for treatment of OSCC drug resistance.
- Subjects :
- Drug
Cancer Research
media_common.quotation_subject
non‐coding RNA (ncRNA)
Reviews
Review
Drug resistance
chemistry.chemical_compound
microRNA
medicine
Humans
CRISPR
RC254-282
media_common
Cisplatin
drug resistance
long non‐coding RNAs
Squamous Cell Carcinoma of Head and Neck
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Cancer
medicine.disease
microRNAs
oral squamous cell carcinoma
stomatognathic diseases
Oncology
Paclitaxel
chemistry
Head and Neck Neoplasms
drug delivery
Drug delivery
Carcinoma, Squamous Cell
Cancer research
Mouth Neoplasms
business
medicine.drug
Subjects
Details
- ISSN :
- 25233548
- Volume :
- 41
- Database :
- OpenAIRE
- Journal :
- Cancer Communications
- Accession number :
- edsair.doi.dedup.....2ad2be262604d78964605b4ee2ccf0e2